Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Myeloproliferative Neoplasias

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Leukemia volume 29, pages 1123–1132 (2015)Cite this article

Subjects

Abstract

Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have gained interest. The randomized CML - Study IV was used for a long-term evaluation of imatinib (IM). 1503 patients have received IM, 1379 IM monotherapy. After a median observation of 7.1 years, 965 patients (64%) still received IM. At 10 years, progression-free survival was 82%, overall survival 84%, 59% achieved MR5, 72% MR4.5, 81% MR4, 89% major molecular remission and 92% MR2 (molecular equivalent to complete cytogenetic remission). All response levels were reached faster with IM800 mg except MR5. Eight-year probabilities of adverse drug reactions (ADR) were 76%, of grades 3–4 22%, of non-hematologic 73%, and of hematologic 28%. More ADR were observed with IM800 mg and IM400 mg plus interferon α (IFN). Most patients had their first ADR early with decreasing frequency later on. No new late toxicity was observed. ADR to IM are frequent, but mostly mild and manageable, also with IM 800 mg and IM 400 mg+IFN. The deep molecular response rates indicate that most patients are candidates for IM discontinuation. After 10 years, IM continues to be an excellent initial choice for most patients with CML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  CAS  PubMed  Google Scholar 

  2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

    Article  CAS  PubMed  Google Scholar 

  3. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.

    Article  CAS  PubMed  Google Scholar 

  4. Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013; 121: 3818–3824.

    Article  CAS  PubMed  Google Scholar 

  5. Falchi L, Kantarjian HM, Wang X, Verma D, Quintas-Cardama A, O'Brien S et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013; 88: 1024–1029.

    Article  CAS  PubMed  Google Scholar 

  6. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–1035.

    Article  CAS  PubMed  Google Scholar 

  7. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515–522.

    Article  CAS  PubMed  Google Scholar 

  8. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.

    Article  CAS  PubMed  Google Scholar 

  9. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260–2270.

    Article  CAS  PubMed  Google Scholar 

  10. Mauro MJ, Deininger MW . Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 409–429.

    Article  CAS  PubMed  Google Scholar 

  11. Salie R, Silver RT . Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2010; 10: 331–335.

    Article  CAS  PubMed  Google Scholar 

  12. Jabbour E, Deininger M, Hochhaus A . Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011; 25: 201–210.

    Article  CAS  PubMed  Google Scholar 

  13. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553–561.

    Article  CAS  PubMed  Google Scholar 

  14. Thanopoulou E, Judson I . The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol 2012; 86: 1–12.

    Article  CAS  PubMed  Google Scholar 

  15. Breccia M, Alimena G . Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. Leuk Res 2013; 37: 713–720.

    Article  CAS  PubMed  Google Scholar 

  16. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Mueller MC, Pletsch N et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634–1642.

    Article  CAS  PubMed  Google Scholar 

  17. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response (MR4.5) is reached by the majority of imatinib-treated patients, predicts survival, and is achieved faster by optimized high-dose imatinib - results from the randomized CML-Study IV. J Clin Oncol 2014; 32: 415–423.

    Article  PubMed  Google Scholar 

  18. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760–6768.

    Article  CAS  PubMed  Google Scholar 

  19. Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096–2102.

    Article  CAS  PubMed  Google Scholar 

  20. Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014; 28: 1988–1992.

    Article  CAS  PubMed  Google Scholar 

  21. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880–1885.

    Article  CAS  PubMed  Google Scholar 

  22. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820.

    Article  CAS  PubMed  Google Scholar 

  23. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041–6051.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686–692.

    Article  CAS  PubMed  Google Scholar 

  25. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172–2175.

    Article  CAS  PubMed  Google Scholar 

  27. Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957–1963.

    Article  PubMed  Google Scholar 

  28. Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol 2014; 140: 1965–1969.

    Article  CAS  PubMed  Google Scholar 

  29. Branford S, Fletcher L, Cross NCP, Müller MC, Hochhaus A, Kim D-W et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330–3338.

    Article  CAS  PubMed  Google Scholar 

  30. Pfirrmann M, Hochhaus A, Lauseker M, Sausele S, Hehlmann R, Hasford J . Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011; 25: 1433–1438.

    Article  CAS  PubMed  Google Scholar 

  31. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006–2013.

    Article  CAS  PubMed  Google Scholar 

  32. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111: 2538–2547.

    Article  CAS  PubMed  Google Scholar 

  33. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC . Dysregulation of bone remodeling by imatinib mesylate. Blood 2010; 115: 766–774.

    Article  CAS  PubMed  Google Scholar 

  34. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022–4028.

    Article  CAS  PubMed  Google Scholar 

  35. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841–851.

    Article  CAS  PubMed  Google Scholar 

  36. Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486–3492.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol 2014; 99: 616–624.

    Article  CAS  PubMed  Google Scholar 

  38. Atallah E, Durand JB, Kantarjian H, Cortes J . Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110: 1233–1237.

    Article  CAS  PubMed  Google Scholar 

  39. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27: 1316–1321.

    Article  CAS  PubMed  Google Scholar 

  40. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; 27: 1310–1315.

    Article  CAS  PubMed  Google Scholar 

  41. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009; 27: 4754–4759.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424–430.

    Article  CAS  PubMed  Google Scholar 

  43. Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008; 112: 3965–3973.

    Article  CAS  PubMed  Google Scholar 

  44. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511–2521.

    Article  CAS  PubMed  Google Scholar 

  45. Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E et al. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 2014; 164: 223–232.

    Article  CAS  PubMed  Google Scholar 

  46. Sasaki K, Kantarjian HM, Jain P, Jabbour E, Pemmaraju N, Wierda WG et al. Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily. J Clin Oncol 2014; 32: Abstract 7024.

    Article  Google Scholar 

  47. Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A et al. Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011; 118: 3228–3235.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The CML IV study was supported by the Deutsche Krebshilfe (Nr. 106642); Deutsches Kompetenznetz für Akute und Chronische Leukämien (BMBF 01GI0270); Deutsche José-Carreras Leukämiestiftung (DJCLS H09/01 f, H06/04v, H03/01, R05/23); European LeukemiaNet (LSHC-CT-2004-503216); Novartis, Nürnberg; Roche, Grenzach-Wyhlen; and Essex Pharma, Munich, all in Germany. We thank Elke Matzat, Andrea Elett, Regina Pleil-Lösch, Inge Stalljann, Gabriele Bartsch, Uwe Böhm, Sabine Dean and all participating investigators with their teams for their contributions.

Author information

Authors and Affiliations

  1. III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany

    L Kalmanti, S Saussele, M C Müller, C T Dietz, L Heinrich, B Hanfstein, U Proetel, A Fabarius, S Rinaldetti & R Hehlmann

  2. Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München, Germany

    M Lauseker, M Pfirrmann & J Hasford

  3. Medizinische Klinik 5, Universitätsklinikum, Erlangen, Germany

    S W Krause

  4. Medizinische Klinik V, Universitätsklinikum, Heidelberg, Germany

    J Dengler

  5. Medizinische Klinik 5, Klinikum Nürnberg Nord, Nürnberg, Germany

    C Falge

  6. Universitätsklinik für Hämatologie, Inselspital, Bern, Switzerland

    E Oppliger-Leibundgut

  7. Klinik für Innere Medizin, Universitätsklinikum, Marburg, Germany

    A Burchert & A Neubauer

  8. Medizinische Klinik II, Universitätsklinikum, Tübingen, Germany

    L Kanz

  9. Klinik für Innere Medizin III, Universitätsklinikum, Ulm, Germany

    F Stegelmann

  10. Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany

    M Pfreundschuh

  11. Medizinische Klinik und Poliklinik III, Ludwig-Maximilians-Universität, München, Germany

    K Spiekermann

  12. Klinik I für Innere Medizin, Universitätsklinikum, Köln, Germany

    C Scheid

  13. Klinik für Innere Medizin II, Universitätsklinikum, Jena, Germany

    A Hochhaus

Authors
  1. L Kalmanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Saussele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Lauseker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M C Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C T Dietz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Heinrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Hanfstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. U Proetel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Fabarius
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S W Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Rinaldetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J Dengler
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C Falge
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. E Oppliger-Leibundgut
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A Burchert
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Neubauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. L Kanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. F Stegelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. M Pfreundschuh
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. K Spiekermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. C Scheid
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. M Pfirrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. A Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. J Hasford
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. R Hehlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the SAKK and the German CML Study-Group

Corresponding author

Correspondence to R Hehlmann.

Ethics declarations

Competing interests

SS has received honoraria from Novartis, Bristol-Myers Squibb (BMS), Pfizer and research funding from Novartis and BMS; MCM honoraria and research funding from Novartis, BMS, ARIAD and Pfizer; BH honoraria from BMS and research funding from Novartis; AN honoraria from Medupdate; CS honoraria for consulting from Novartis; MP honoraria from BMS and consultancy from Novartis; AH honoraria from Novartis, BMS,ARIAD, consultancy from Novartis and research funding from Novartis, ARIAD and Pfizer and RH has research funding from Novartis and BMS. The remaining authors declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalmanti, L., Saussele, S., Lauseker, M. et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29, 1123–1132 (2015). https://doi.org/10.1038/leu.2015.36

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.36

This article is cited by

Search

Advanced search

Quick links